From Checklists to Culture: Lessons from PDA Regulatory Confrence 2025
From Checklists to Culture: Lessons from PDA Regulatory Confrence 2025
September 18, 2025
"Advancing public health requires change."
At the Parental Drug Association (PDA) Regulatory Conference 2025 there was one message that appeared as a refrain in every session: compliance is no longer enough. True resilience in pharma means a step away from box-ticking towards a culture of quality, risk-based governance, and prudent application of technology.
Knowing When to Walk Away
Day 1 started with a harsh truth: Sometimes, shiny facilities aren't worth it. In a case study, it was noted how a new aseptic CMO continued to fail due to cultural and operating cracks, from staff surveillance gaps to inconsistent aseptic practices. The lesson learned: Due diligence is more than financial and technical; it's people, culture, and lifecycle alerts. Out-of-synch partners in pharma can stall launches and blow resources. Leaders were warned: don’t jump headfirst into collaborations, and don’t ignore red flags.
Beyond FMEA: Rethinking Risk
Traditional FMEA (Failure Modes and Effects Analysis) works with machines, not humans. Drowsiness, stress, and distractions don’t come easily in terms of probabilities. Experts, instead, urged companies to think about vulnerability:
- Manual-only = high vulnerability
- SOP/audit-trail controlled = medium vulnerability
- Engineering/technical controls = low vulnerability
The DOM (Design–Operation–Monitoring) of governance was outlined as the future: lean processes, empowered employees, and feedback that feeds back into redesign, as opposed to constant retraining.
The FDA put it simply in one sentence: garbage in equals garbage out; waste is risk. Lengthy elaborate SOPs, over-witnessing of events, and redundant measures don’t ensure quality, they breed new errors.
Fix the System, Not the Symptom
On Day 3, what happens after the warning letter was the topic of discussion for regulators. Post-Warning Letter Meetings (PWLMs) were defined not as negotiation, but as advisory checkpoints, an opportunity to show systemic change, not superficial solutions. The mantra was repeated often: “Fix the system, not the symptom.” Organizations that downscope, offer quick fixes, or resort solely to retraining send the wrong cultural signal. FDA guidance came clear: approach equipped with data, root cause analysis, and CAPAs that are sustainable.
AI: Promise and Pitfalls
On each of the three days, AI emerged as opportunity and risk. On Day 1, software such as SPARC and AGILI-T demonstrated how GenAI can automate supplier tracking as well as deviation management. By Day 2, the message was clear: AI can author reports, recommend CAPAs, and condense data, but only under human expert guidance.
Garbage in = garbage out. Unless data, governance, and expert oversight are clean, AI is nothing more than a risk. Specifically, regulators confirmed that they aren’t yet using AI in inspection activities. So far, AI remains an administrative aide, not a replacement for judgment.
The Culture Shift
If there is one takeaway that holds PDA Reg 2025 together, it’s this: quality is cultural. Compliance will always be important, but what saves patients, and reputations, is ownership, empowerment, and resilience.
- Resilience involves rebounding after setbacks due to good communication and common purpose.
- Ownership means getting employees to think of quality as internal to them, rather than an imperative.
- Communication includes transparent relationships with CMOs, inspectors, and regulators, no surprises, no silos.
“Quality is like a guardian dog that guides the sheep. It’s with everybody at the organization, not an end-all, be-all, but a guide.”
Final Word
Pharma stands at a crossroads. Box-ticking and checklists will not move companies forwards. Lean governance, cultural ownership, and judicious AI integration will. At PDA Reg 2025, there was a clear message: simplify, empower, and prepare, because at the end of the day, quality isn’t compliance, it’s trust.
Disclaimer: This is a recount and notes from PDA regulatory conference by Zephaniah Odidika